Catalyst Financial Partners LLC raised its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 2.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,368 shares of the company’s stock after acquiring an additional 85 shares during the period. Eli Lilly and Company makes up 0.7% of Catalyst Financial Partners LLC’s investment portfolio, making the stock its 24th largest position. Catalyst Financial Partners LLC’s holdings in Eli Lilly and Company were worth $2,546,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of the company. Lipe & Dalton bought a new stake in Eli Lilly and Company in the fourth quarter valued at $26,000. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company in the third quarter worth approximately $27,000. Optiver Holding B.V. purchased a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $36,000. Family CFO Inc bought a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $40,000. Finally, O Brien Wealth Partners LLC raised its holdings in Eli Lilly and Company by 70.5% in the 4th quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after acquiring an additional 31 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.
Eli Lilly and Company Stock Down 0.4 %
Shares of NYSE LLY traded down $3.45 during midday trading on Thursday, reaching $771.55. 2,317,073 shares of the company’s stock were exchanged, compared to its average volume of 3,068,803. Eli Lilly and Company has a 52-week low of $419.80 and a 52-week high of $800.78. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The stock has a market capitalization of $733.28 billion, a PE ratio of 113.63, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37. The business’s fifty day moving average price is $761.56 and its two-hundred day moving average price is $675.58.
Eli Lilly and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be issued a dividend of $1.30 per share. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.
Analyst Ratings Changes
Several research analysts have recently weighed in on the company. The Goldman Sachs Group boosted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Barclays boosted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Finally, Citigroup lifted their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $757.95.
Read Our Latest Research Report on LLY
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Airline Stocks – Top Airline Stocks to Buy Now
- Roblox: The Bottom Just Fell Out of the Metaverse
- 3 Warren Buffett Stocks to Buy Now
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- Stock Average Calculator
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.